The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.85
Bid: 2.80
Ask: 2.90
Change: 0.00 (0.00%)
Spread: 0.10 (3.571%)
Open: 2.85
High: 2.85
Low: 2.85
Prev. Close: 2.85
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

27 Oct 2023 11:33

RNS Number : 5779R
Panmure Gordon (UK) Limited
27 October 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Panmure Gordon (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Allergy Therapeutics plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Allergy Therapeutics plc

(d) Date dealing undertaken:

26 Oct 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

0.1p ordinary

Purchase

 

716,099

0.0132

 

0.0127

 

0.1p ordinary

Sales

700,280

0.01428

 

0.01428

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing, or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

27/10/2023

Contact name:

Freddie Wooding

Telephone number:

+44 (0)20 7886 2969

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERFZMZGGNZGFZM
Date   Source Headline
3rd Apr 20247:00 amRNSDirector Resignation
27th Mar 20247:00 amRNSUpdate on funding
27th Mar 20247:00 amRNSInterim Results for six months ended 31 Dec 2023
12th Mar 20248:59 amRNSVLP Peanut PROTECT Trial Update
12th Mar 20247:00 amRNSVLP Peanut PROTECT Trial Update
11th Mar 20247:00 amRNSAppointment of Shaun Furlong to Board of Directors
8th Mar 20241:49 pmRNSResult of AGM
14th Feb 20247:00 amRNSHalf-Year Trading Update 2024
9th Feb 20243:07 pmRNSNotice of 2023 Annual General Meeting
30th Jan 20247:30 amRNSRestoration - Allergy Therapeutics plc
30th Jan 20247:00 amRNSPublication of Annual Report and Accounts 2023
4th Jan 202412:29 pmRNSTotal Voting Rights
2nd Jan 20247:30 amRNSSuspension - Allergy Therapeutics plc
27th Dec 202312:01 pmRNSAmendment to existing Facility Agreement
15th Dec 202312:48 pmRNSAnnual Report and Accounts Delayed
13th Dec 20234:54 pmRNSPDMR dealing and Total Voting Rights
13th Dec 20237:00 amRNSG306 Phase III trial meets key endpoints
11th Dec 20237:00 amRNSUpdate on funding
1st Dec 20237:00 amRNSTotal Voting Rights
28th Nov 20233:03 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSG306 Grass Phase III trial meets primary endpoint
10th Nov 20232:39 pmRNSForm 8.5 (EPT/RI)
10th Nov 20231:22 pmRNSDirector/PCA Dealing
10th Nov 20231:11 pmRNSHolding(s) in Company
10th Nov 20237:00 amRNSOffer Closure
9th Nov 202310:48 amRNSExercise of Options and Total Voting Rights
9th Nov 20239:24 amRNSForm 8.5 (EPT/RI)
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202310:45 amRNSForm 8.5 (EPT/RI)
7th Nov 202311:10 amRNSForm 8.5 (EPT/RI)
6th Nov 20239:33 amRNSForm 8.5 (EPT/RI)
6th Nov 20237:00 amRNSUpdate on funding
3rd Nov 20239:31 amRNSForm 8.5 (EPT/RI)
2nd Nov 202310:24 amRNSForm 8.5 (EPT/RI)
1st Nov 202310:23 amRNSForm 8.5 (EPT/RI)
31st Oct 20238:30 amRNSForm 8.5 (EPT/RI)
30th Oct 202310:06 amRNSForm 8.5 (EPT/RI)
27th Oct 202311:33 amRNSForm 8.5 (EPT/RI)
26th Oct 202310:07 amRNSForm 8.5 (EPT/RI)
25th Oct 20239:48 amRNSForm 8.5 (EPT/NON-RI)
25th Oct 20238:43 amRNSForm 8.5 (EPT/RI)
24th Oct 20238:29 amRNSForm 8.5 (EPT/RI)
23rd Oct 20238:23 amRNSForm 8.5 (EPT/RI)
20th Oct 20235:17 pmRNSHolding(s) in Company
20th Oct 20239:02 amRNSForm 8.5 (EPT/RI)
19th Oct 20238:38 amRNSForm 8.5 (EPT/RI)
19th Oct 20237:00 amRNSPosting of Offer Document
18th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
17th Oct 202310:31 amRNSForm 8.5 (EPT/RI)
16th Oct 20235:39 pmRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.